CardioCell To Pursue Large-Scale Chronic Heart Failure Trial For IV Stem Cell Therapy
Executive Summary
CardioCell has presented data from the first clinical trial to demonstrate the safety and viability of intravenous (IV) ischemia-tolerant mesenchymal stem cells in chronic heart failure patients – dispelling the theory that only large amounts of stem cells delivered directly to the myocardium would achieve improvements in patient outcomes.
You may also be interested in...
Brilinta No Better Than Aspirin In Stroke Trial
Topline data from the SOCRATES trial of Brilinta (Brilique; ticagrelor) provided more ammunition for those pushing for AstraZeneca's CEO Pascal Soriot to have his pay linked to performance.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.